Brown Sydney E S, Meltzer David O, Chin Marshall H, Huang Elbert S
The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
J Am Geriatr Soc. 2008 Jul;56(7):1183-90. doi: 10.1111/j.1532-5415.2008.01757.x. Epub 2008 May 19.
To assess whether patient perceptions of treatments for diabetes mellitus differ according to clinical criteria such as limited life expectancy and functional decline (i.e., vulnerability).
Cross-sectional survey.
Clinics affiliated with two Chicago-area hospitals.
Patients aged 65 and older living with type 2 diabetes mellitus (N=332).
Utilities (quantitative measures of preference on a scale from 0 to 1, with 0 representing a state equivalent to death and 1 representing life in perfect health) were assessed for nine hypothetical treatment states using time trade-off questions, and patients were queried about specific concerns regarding medications. Vulnerability was defined according to the Vulnerable Elders Scale.
Thirty-six percent of patients were vulnerable. Vulnerable patients were older (77 vs 73) and had diabetes mellitus longer (13 vs 10 years; P<.05). Vulnerable patients reported lower utilities than nonvulnerable patients for most individual treatment states (e.g., intensive glucose control, mean 0.61 vs 0.72, P<.01), but within group variation was large for both groups (e.g., standard deviations >0.25). Although mean individual state utilities differed across groups, no significant differences were found in how vulnerable and nonvulnerable patients compared intensive and conventional treatment states (e.g., intensive vs conventional glucose control). In multivariable analyses, the association between vulnerability and individual treatment state utilities became nonsignificant except for the cholesterol pill.
Older patients' preferences for intensity of treatment for diabetes mellitus vary widely and are not closely associated with vulnerability. This observation underscores the importance of involving older patients in decisions about treatment for diabetes mellitus, irrespective of clinical status.
评估糖尿病患者对治疗的看法是否会根据诸如预期寿命有限和功能衰退(即脆弱性)等临床标准而有所不同。
横断面调查。
芝加哥地区两家医院附属的诊所。
65岁及以上的2型糖尿病患者(N = 332)。
使用时间权衡问题评估了九种假设治疗状态的效用(从0到1的偏好定量测量,0代表等同于死亡的状态,1代表完全健康的生活),并询问患者对药物的具体担忧。根据脆弱老年人量表定义脆弱性。
36%的患者属于脆弱群体。脆弱患者年龄更大(77岁对73岁),患糖尿病的时间更长(13年对10年;P <.05)。在大多数个体治疗状态下,脆弱患者报告的效用低于非脆弱患者(例如,强化血糖控制,平均值0.61对0.72,P <.01),但两组内的个体差异都很大(例如,标准差>0.25)。尽管各治疗状态下的平均效用在两组间存在差异,但在比较强化和常规治疗状态(例如,强化与常规血糖控制)时,脆弱和非脆弱患者之间未发现显著差异。在多变量分析中,除了胆固醇药物外,脆弱性与个体治疗状态效用之间的关联变得不显著。
老年患者对糖尿病治疗强度的偏好差异很大,且与脆弱性没有密切关联。这一观察结果强调了让老年患者参与糖尿病治疗决策的重要性,无论其临床状况如何。